NCT02675946 2022-01-26CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)Curegenix Inc.Phase 1 Unknown72 enrolled